Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Arbutus Biopharma Corporation (ABUS)
NASDAQ:ABUS
Holding ABUS?
Track your performance easily
ABUS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.27 - $4.73
Previous CloseN/A
Volume149.14K
Average Volume (3M)827.78K
Market Cap
$629.11M
Enterprise Value$606.61M
Total Cash (Recent Filing)$130.56M
Total Debt (Recent Filing)$12.00M
Price to Earnings (P/E)―
Beta0.35
Next Earnings
Feb 27, 2025EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.43
Shares Outstanding189,491,680
10 Day Avg. Volume684,171
30 Day Avg. Volume827,778
Standard Deviation0.25
R-Squared0.14
Alpha0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)93.31
Price to Cash Flow (P/CF)-7.60
P/FCF Ratio0.00
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue89.97
Enterprise Value/Gross Profit33.44
Enterprise Value/Ebitda-8.13
Forecast
1Y Price Target
$4.75Price Target Upside40.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Arbutus Biopharma News
PremiumCompany Announcements
Arbutus Biopharma Highlights Hepatitis B Treatment Advances
PremiumCompany Announcements
Arbutus Biopharma’s Promising cHBV Treatment Results
PremiumCompany Announcements
Arbutus Biopharma’s Trial Boosts Hepatitis B Treatment
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe initiation of the new Phase 2b trial is seen as a major milestone for Arbutus, reinforcing the positive outlook for the company's future developments.
Financial OutlookManagement estimates its cash holdings to sufficiently fund its operations through the first quarter of 2028, allowing for the full funding of the upcoming imdusiran Phase 2b trial.
Therapeutic DevelopmentsAnalyst affirms a buy rating for Arbutus Biopharma, indicating confidence in the company's therapeutic developments.
Bears Say
Legal ChallengesLNP litigation process continues, with ongoing legal challenges against Pfizer/BioNTech and Moderna.
Market And Treatment AdoptionKOL commentary at the meeting was mixed, with some saying that PEG-IFN needs to be brought back into the treatment regimen in the U.S., others saying they do not and will not use it.
Research And Development RisksKey risks include failed or equivocal studies, unforeseen safety or tolerability issues, meaningful delays, and the inability to sufficiently fund operations.
---
Ownership Overview
1.90% Insiders
10.23% Mutual Funds
0.04% Other Institutional Investors
77.50% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ABUS FAQ
What was Arbutus Biopharma Corporation’s price range in the past 12 months?
Arbutus Biopharma Corporation lowest stock price was $2.27 and its highest was $4.72 in the past 12 months.
What is Arbutus Biopharma Corporation’s market cap?
Arbutus Biopharma Corporation’s market cap is $629.11M.
When is Arbutus Biopharma Corporation’s upcoming earnings report date?
Arbutus Biopharma Corporation’s upcoming earnings report date is Feb 27, 2025 which is in 27 days.
How were Arbutus Biopharma Corporation’s earnings last quarter?
Arbutus Biopharma Corporation released its earnings results on Nov 06, 2024. The company reported -$0.1 earnings per share for the quarter, missing the consensus estimate of -$0.094 by -$0.006.
Is Arbutus Biopharma Corporation overvalued?
According to Wall Street analysts Arbutus Biopharma Corporation’s price is currently Undervalued.
Does Arbutus Biopharma Corporation pay dividends?
Arbutus Biopharma Corporation does not currently pay dividends.
What is Arbutus Biopharma Corporation’s EPS estimate?
Arbutus Biopharma Corporation’s EPS estimate is -0.08.
How many shares outstanding does Arbutus Biopharma Corporation have?
Arbutus Biopharma Corporation has 189,491,680 shares outstanding.
What happened to Arbutus Biopharma Corporation’s price movement after its last earnings report?
Arbutus Biopharma Corporation reported an EPS of -$0.1 in its last earnings report, missing expectations of -$0.094. Following the earnings report the stock price went down -1.01%.
Which hedge fund is a major shareholder of Arbutus Biopharma Corporation?
Among the largest hedge funds holding Arbutus Biopharma Corporation’s share is Saba Capital Management. It holds Arbutus Biopharma Corporation’s shares valued at 3M.
---
Arbutus Biopharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.75 (40.53% Upside)
$4.75 (40.53% Upside)
Blogger Sentiment
Bullish
ABUS Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 233.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.9%
Last 30 Days ▲ 1.8%
Last 30 Days ▲ 1.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
41.27%
12-Months-Change
Fundamentals
Return on Equity
-67.81%
Trailing 12-Months
Asset Growth
-11.47%
Trailing 12-Months
Company Description
Arbutus Biopharma Corporation
Arbutus Biopharma Corp. engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company is headquartered in Burnaby, Canada.
---
ABUS Stock 12 Month Forecast
Average Price Target
$4.75
▲(40.53% Upside)
Technical Analysis
Gilead Sciences
―
Ionis Pharmaceuticals
―
Vertex Pharmaceuticals
―
Sarepta Therapeutics
―
Moderna
―
Best Analysts Covering ABUS
1 Year
1 Year Success Rate
16/32 ratings generated profit
1 Year Average Return
+6.08%
reiterated a buy rating 19 days ago
Copying Roy Buchanan's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +6.08% per trade.
---